miRoncol’s oncology research established a published application of its microRNA intelligence approach. That work now informs miCheckup, the dedicated Early Cancer Detection Test.
Testing details, eligibility, clinical information, ordering and product-specific disclosures belong on the dedicated miCheckup website.
Develops microRNA measurement, AI-assisted pattern analysis, longitudinal research and the broader application portfolio.
Provides the cancer-specific test experience, including who it is for, how it works, ordering and important clinical information.
Two peer-reviewed studies form the public scientific foundation for miRoncol’s blood-based microRNA approach to multi-cancer detection.
In plain language: the study examined whether microRNA patterns in serum could distinguish multiple cancers from non-cancer samples.
Zhang J, Rui H, Hu H. Scientific Reports 14, 22136.
Read the paper ↗In plain language: this earlier work developed and evaluated the model that became the research starting point for miRoncol’s approach.
Zhang A, Hu H. Cancers 14(6), 1450.
Read the paper ↗Published research does not by itself establish performance for every population, sample type or intended use. Product-specific validation and disclosures are provided through miCheckup.
microRNAs participate in post-transcriptional gene regulation. Evaluating patterns across this regulatory layer may add information that differs from a single downstream biomarker or a structural image.
The approach evaluates disease-associated patterns within the microRNA profile.
AI-assisted models help recognize disease-associated patterns within the microRNA profile.
A screening signal is information for appropriate follow-up, not a standalone diagnosis or treatment decision.
The public product is the end of a translation pathway. It is not simply a research model placed into the market.
Identify biologically and analytically meaningful microRNA patterns in relevant datasets.
Evaluate performance, limitations and generalizability in appropriate samples and cohorts.
Specify the intended use, test workflow and the focused signal set required for that question.
Present results with clear limitations and appropriate pathways for physician-led follow-up.
Learn who the test is for, how the process works, what the result means and which important limitations to understand.